BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24403235)

  • 21. Pancreastatin predicts survival in neuroendocrine tumors.
    Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study.
    Zhu LM; Tang L; Qiao XW; Wolin E; Nissen NN; Dhall D; Chen J; Shen L; Chi Y; Yuan YZ; Ben QW; Lv B; Zhou YR; Bai CM; Chen J; Song YL; Song TT; Lu CM; Yu R; Chen YJ
    Medicine (Baltimore); 2016 Feb; 95(7):e2836. PubMed ID: 26886644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
    Else T; Jonasch E; Iliopoulos O; Beckermann KE; Narayan V; Maughan BL; Oudard S; Maranchie JK; Iversen AB; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R
    Clin Cancer Res; 2024 May; 30(9):1750-1757. PubMed ID: 38393723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
    Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
    Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
    Klieser E; Urbas R; Stättner S; Primavesi F; Jäger T; Dinnewitzer A; Mayr C; Kiesslich T; Holzmann K; Di Fazio P; Neureiter D; Swierczynski S
    Hum Pathol; 2017 Jul; 65():41-52. PubMed ID: 28235630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors.
    Crippa S; Partelli S; Zamboni G; Scarpa A; Tamburrino D; Bassi C; Pederzoli P; Falconi M
    Surgery; 2014 Jan; 155(1):145-53. PubMed ID: 24646958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
    Bilimoria KY; Bentrem DJ; Merkow RP; Tomlinson JS; Stewart AK; Ko CY; Talamonti MS
    J Am Coll Surg; 2007 Oct; 205(4):558-63. PubMed ID: 17903729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior.
    Díaz Del Arco C; Esteban López-Jamar JM; Ortega Medina L; Díaz Pérez JÁ; Fernández Aceñero MJ
    Diagn Cytopathol; 2017 Jan; 45(1):29-35. PubMed ID: 27863178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
    Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
    Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution.
    Yang M; Zeng L; Zhang Y; Wang WG; Wang L; Ke NW; Liu XB; Tian BL
    Medicine (Baltimore); 2015 Mar; 94(12):e660. PubMed ID: 25816036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
    Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
    World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
    Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of Pancreatic Neuroendocrine Tumour Grading by Endoscopic Ultrasound-Guided Fine Needle Aspiration: Analysis of a Large Cohort and Perspectives for Improvement.
    Boutsen L; Jouret-Mourin A; Borbath I; van Maanen A; Weynand B
    Neuroendocrinology; 2018; 106(2):158-166. PubMed ID: 28494461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the prognostic values of the 2010 WHO classification, AJCC 7th edition, and ENETS classification of gastric neuroendocrine tumors.
    Kim BS; Park YS; Yook JH; Kim BS
    Medicine (Baltimore); 2016 Jul; 95(30):e3977. PubMed ID: 27472674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target.
    Gurung B; Hua X; Runske M; Bennett B; LiVolsi V; Roses R; Fraker DA; Metz DC
    Cancer Biol Ther; 2015; 16(2):219-24. PubMed ID: 25482929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Staging accuracy of MR for pancreatic neuroendocrine tumor and imaging findings according to the tumor grade.
    Kim JH; Eun HW; Kim YJ; Han JK; Choi BI
    Abdom Imaging; 2013 Oct; 38(5):1106-14. PubMed ID: 23728305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.